Skip to content

United Therapeutics UTHR Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$1.29B-3.5%$1.33B+5.0%$1.27B+2.4%$1.24B+2.6%$1.21B+1.3%
$88.4M+3.3%$85.6M+3.8%$82.5M+3.5%$79.7M+3.1%$77.3M+6.6%
$149.8M+1.4%$147.7M+8.8%$135.7M-1.9%$138.3M-7.9%$150.2M+4.3%
$1.56B+0.1%$1.56B+0.3%$1.56B+13.5%$1.37B-2.9%$1.41B+6.4%
$546.4M+5.0%$520.5M+19.8%$434.3M+44.6%$300.3M+6.0%$283.2M+14.9%
$2.5B+150%$1B
$700M+75.0%$400M0.0%
-$2.64B-111%-$1.25B+5.6%-$1.32B-207%-$431.2M-53.7%-$280.6M+77.6%
-$213.8M-190%$237.4M-63.4%$648.4M+32.5%
$1.02B-2.3%$1.04B-7.2%$1.12B+4.8%$1.07B-5.1%$1.13B+4.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does United Therapeutics generate?
United Therapeutics (UTHR) generated $1.6B in operating cash flow over the trailing twelve months.
What is United Therapeutics's free cash flow?
After $546.4M of capital expenditures, United Therapeutics's free cash flow was $1.0B over the trailing twelve months, down 9.9% year over year.
Where does United Therapeutics's cash flow data come from?
Every line is extracted from United Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.